ATRA Atara Biotherapeutics Inc.

12.35
-0.92  -7%
Previous Close 13.26
Open 13.16
Price To Book 2.86
Market Cap 663,642,041
Shares 53,757,962
Volume 428,664
Short Ratio
Av. Daily Volume 771,005
Stock charts supplied by TradingView

NewsSee all news

  1. Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

    Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference

  2. Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

    ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday, September 13, 2019, at

  3. Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data presented at ECTRIMS September 13, 2019. Further data due in 2020.
ATA188
Multiple sclerosis
BLA filing due 2H 2020. Phase 3 top-line data due prior to filing but will only release data until after acceptance of the BLA filing.
ATA 129 (tab-cel) - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
BLA filing due 1H 2020. Phase 3 top-line data due prior to filing but will only release data until after acceptance of the BLA filing.
ATA 129 (tab-cel) - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial ongoing.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 1 presentation at ASCO June 4, 2019. ORR 63% in patients who also received chemo + pembrolizumab.
Autologous T Cells
Malignant pleural disease
Phase 2 trial to be initiated 2H 2020.
ATA 129
Epstein-Barr virus + other various cancers

Latest News

  1. Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

    Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference

  2. Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

    ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday, September 13, 2019, at

  3. Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with